Meet Neha, a 42-year-old RA patient1 who has an increased risk of serious infections due to multiple factors.2-4
‘I was shocked when my doctor told me that I have RA – especially when I learned that my disease activity is considered high.3’
‘I’ve always been generally healthy, although I am a smoker2 and was recently hospitalised for pneumonia.4’
‘I’ve heard that some treatments for RA can increase the risk of infections2 – and that scares me a lot’.
~2× increased risk of serious bacterial infections with TNFi treatment.5,*
Note: This is a hypothetical case for representation purpose only.
‘I’ve always been generally healthy, although I am a smoker and was recently hospitalised for pneumonia’.
Patients such as Neha benefit from a lower risk of serious infections with Enbrel®6,7
From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.6,†
Unadjusted Incidence Rate of a First Serious Infection6
Adapted from van Dartel SA, et al. 2013.
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From a retrospective study that compared 2393 patients with RA who received TNFi versus 2933 patients with RA who received MTX. Compared with patients who received MTX alone: adjHR = 1.9 (95% CI, 1.3-2.8).5
†Among 2356 patients with RA followed up to 5 years in the DREAM biological registry.6
Study design: van Dartel SA, et al. 2013.
The objective of this study was to analyse whether the risk of serious infections in patients with RA starting TNF-inhibiting therapy is different for adalimumab, infliximab and Enbrel®, in a head-to-head comparison with a follow-up time of up to 5 years. Data were extracted from the DREAM biological registry (since 2003) and a preceding biological registry from the RUNMC (before 2003), both with the same inclusion criteria and work flow. Incidence rates were calculated from the observed number of first serious infections for a follow-up time of up to 5 years. A Cox proportional hazards model with time-to-first-serious infection was used to estimate risk differences among the TNFi treatment groups, with correction for confounders.6
Serious infections in patients treated with Enbrel® versus adalimumab: adjHR = 0.55 (95% CI, 0.44-0.67); Enbrel® versus infliximab: adjHR = 0.49 (95% CI, 0.29-0.83).6
‡Results of a systematic review of 10 randomised trials and 51 observational studies that evaluated a total of >100,000 patients.
The majority of evaluated trials/studies (70%) was conducted in patients with RA.7
adjHR, adjusted hazard ratio; AE, adverse event; CI, confidence interval; DREAM, Dutch RhEumatoid Arthritis Monitoring; MTX, methotrexate; RA, rheumatoid arthritis; RUNMC, Radboud University Nijmegen Medical Centre; SmPC, summary of product characteristics; TNF, tumour necrosis factor; TNFi, tumour necrosis factor inhibitor.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.5,†
From the DREAM biological registry, which included 2356 patients with RA followed up to 5 years.5,†
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.